665. In vitro Activity of Omadacycline Against Recent (2018) Bacterial Pathogens from the United States and Europe Obtained from Skin and Skin Structure, Respiratory, and Urinary Tract Infections

BACKGROUND: Omadacycline (OMC) was FDA approved to treat acute bacterial skin and skin structure infection (ABSSSI) and community-acquired bacterial pneumonia (CABP) for indicated organisms in 2018. Phase 2 OMC clinical trials for uncomplicated urinary tract infection (uUTI; NCT03425396) and acute p...

Descripción completa

Detalles Bibliográficos
Autores principales: Huband, Michael D, Pfaller, Michael A, Streit, Jennifer M, Sader, Helio S, Flamm, Robert K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811136/
http://dx.doi.org/10.1093/ofid/ofz360.733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6811136/
http://dx.doi.org/10.1093/ofid/ofz360.733

Ejemplares similares